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Abstract 
Formulating drugs into nanoparticles offers many attractive advantages over free drugs 
including improved bioavailability, minimized toxic side effects, enhanced drug delivery, 
feasibility of incorporating other functions such as controlled release, imaging agents for 
imaging, targeting delivery, loading more than one drug for combination therapies. One of the 
key parameters is drug loading which is defined as the mass ratio of drug to drug-loaded 
nanoparticles. Currently, most nanoparticle systems have relatively low drug loading (<10 
wt%). How to increase drug loading remains a challenge. This review presents an overview of 
recent research on developing nanoparticles with high drug loading (>10 wt%) from the 
perspective of synthesizing strategies, including post-loading, co-loading, and pre-loading. 
Based on these three different strategies, various nanoparticle systems with different materials 
and drugs are summarized and discussed in terms of their synthesis methods, drug loadings, 
encapsulation efficiencies, release profiles, stabilities, and their applications in drug delivery. 
The advantages and disadvantages of these strategies are discussed with an objective of 
providing useful design rules for future development of high drug loading nanoparticles. 
 
1. Introduction 
Nanotechnology has made tremendous progress in the past decades in the development of 
nanomedicine. Formulating drugs into nanoparticles - nanomedicine - endows drugs with new 
properties such as improved bioavailability and pharmacokinetics, reduced toxic side effects, 
controlled release, and possibility of elevating drug dose, etc. For example, many effective 
therapeutic drugs are water insoluble limiting their clinical applications.[1] Forming 
hydrophobic drug loaded nanomedicines not only improves their solubility, bioavailability, 
stability, biodistribution, pharmacokinetics, and pharmacodynamics,[2] but also decreases drug 
toxicity and enhances therapeutic efficacy.[3] Furthermore, other functionalities such as 
imaging, triggered release and targeting delivery can be incorporated into nanomedicines to 
achieve multifunctions.[4]  
Numerous nanomedicines have been developed based on various nanoparticle drug delivery 
systems, including polymer nanoparticles,[5] liposomes,[6] inorganic nanoparticles,[7] drug 
conjugates,[8] hydrogel nanoparticles,[9] viral nanoparticles,[10] metal-organic framework 
(MOF),[11] etc. However, despite enormous research efforts and substantial investments over 
the past decades, only a handful of nanomedicines have been approved by the US Food and 
Drug Administration (FDA) for clinical applications such as Doxil (doxorubicin encapsulated 
by polyethylene glycol (PEG) coated liposome) and Abraxane® (albumin–bound paclitaxel 
nanoparticle).[12] One of the factors hindering the clinical translation of nanomedicine is drug 
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loading. Insufficient drug loading with uncontrolled drug release represents one of the key 
challenges.  
Most nanomedicines have low drug loading (typically a few weight percent). The clinical 
translation of such nanomedicines is challenging due to hurdles like high production cost, 
problems in scale-up productions with reproducible properties, and possible toxic side-effects 
from the nanomaterials. Furthermore, to achieve a drug therapeutic window, very high particle 
concentration is required, but the very viscous solution of such high NP concentration leads to 
difficulties in i.v. injection.[13], [14] Thus, it is critical to increase drug loading thus minimizing 
these adverse effects.[15] In contrast, with high drug-loading nanoparticles, minimum amount 
of nanoparticles are needed to achieve the therapeutic level, which can not only reduce the 
potential adverse effect from the over-dosed materials, but also decrease the manufacturing 
cost of the nanomedicine.[16] Therefore, high drug-loading nanoparticles would be ideal to 
achieve the high drug dose with a reduced amount of carrier material.[17] These advantages of 
high drug-loading nanomedicine become even more beneficial for those well-tolerated drugs 
so its doses can significantly escalated. Also, the route of administration has a direct impact on 
the formulation of nanomedicines. For oral delivery, the mucus gel layer is a considerable 
barrier for nanoparticles to reach the absorption membrane, the cut-off size for mucus 
permeability is around 100 nm.[18] For systematic i.v. administration, nanoparticles with sizes 
ranging from 10 to 150 nm are considered optimal for the enhanced permeability and retention 
(EPR) effect [4a, 19] although this EPR effect is under intense debate. Moreover, nanoparticles 
with smaller size could penetrate deeper, thus may achieve better anti-tumor effect.[20] 
Drug loading is a critical parameter in developing drug-loaded nanoparticles. Drug loading and 
encapsulation efficiency are defined in different ways in different studies, which makes it very 
difficult to directly compare different nanoparticle systems. Herein, drug loading and 
encapsulation efficiency are defined as follows:[21] 
 
Drug loading = 
mass of the drug
total mass of the drug loaded nanoparticles 
= 
wdrug
wdrug + wnanocarrier
                     (1) 
Encapsulation efficiency = 
weight of the drug in nanoparticles
weight of drug added
 = 
wdrug in nanoparticles
wdrug added
              (2) 
 
All the drug loading and encapsulation efficiency are recalculated using these two equations 
for all the literature reviewed in this paper. Although a variety of nanoparticle systems with 
distinct characteristics have been successfully synthesized, the drug loading of most 
nanoparticle systems is relatively low (generally less than 10%).[22]  Therefore, it is urgent to 
develop strategies to improve drug loading. 
 
This review focuses on summarizing and comparing different loading strategies for fabricating 
nanoparticles with high drug loading (>10%). According to the approaches adopted in 
literature, we classify drug loading strategies into three categories: post-loading, co-loading, 
and pre-loading. Each of them is reviewed with examples of nanoparticles having different 
materials and drugs. Their synthesis methods, drug loadings, encapsulation efficiencies, release 
profiles, stabilities as well as their drug efficacy are introduced. Furthermore, the advantages 
and disadvantages of these strategies are also discussed. 
 
10.1002/cplu.202000496
Ac
ce
pt
ed
 M
an
us
cr
ip
t
ChemPlusChem
This article is protected by copyright. All rights reserved.
4 
 
2. Strategies for fabricating high drug-loading nanoparticles  
Three key strategies have been developed for fabricating high drug-loading nanoparticles 
including post-loading, co-loading, and pre-loading (Figure 1). According to the specific 
properties of a particular nanoparticle (materials, structure, surface properties, etc.), one 
approach could be adopted to achieve high drug loading. The post-loading strategy usually 
synthesizes porous nanocarriers (such as silica, carbon, MOF, etc.), which are then mixed with 
a drug solution to allow the drug loaded to the nanoparticles through various mechanisms such 
as adsorption, electrostatic interactions, entrapment, hydrophobic forces etc. (Figure 1a). The 
co-loading method often adopts a strategy through conjugating a drug to a polymer or 
macromolecule, then the self-assembly of drug conjugates leads to formation of drug-loaded 
nanoparticles (Figure 1b). The pre-loading strategy generally forms drug nanoparticles first, 
followed by coating with a layer of other materials thus forming nanoparticles with a drug core 
and a protective shell structure (Figure 1c). 
 
 
Figure 1. Three representative strategies for making high drug-loading nanoparticles. a, Post-
loading. b, Co-loading. c, Pre-loading. 
 
Based on the definition of drug loading, here we summarized recent progress of high drug-
loading (≥10%) nanoparticles in Table 1. The three strategies are discussed in detail in the 
following sections. 
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Table 1. Various high drug-loading nanoparticles 
Loading 
strategy 
Nanocarrier 
material 
Drug Drug loading (%) 
Encapsulation 
efficiency (%) 
Size (nm) PDI Stability t1/2 release Reference 
Post-
loading 
Calcium silicate 
hydrate 
Docetaxel; Hemoglobin; 
Ibuprofen 
Docetaxel 7.6; 
Hemoglobin 49.9; 
Ibuprofen 65.5 
Ibuprofen 100 30-50 - - 
Docetaxel 0-2 h at pH 5.5; 
Docetaxel 10-15 h at pH 
7.4; Ibuprofen 30-50 h in 
simulated body fluid 
[23] 
Carbon 
Camptothecin 17 - 200 - - >130 h in water [24] 
Doxorubicin 51.9 - 255 0.042 >12 h >48 h in PBS [25] 
Lovastatin 25.63-36.26 - 500-800 - - 0-10 min [26] 
Hydrogel Doxorubicin 16.0-42.3 73.2-95.7 
160-610 
(TEM) 
- - 
0-2.5h at pH 5.0 with 10 mM 
glutathione; >24 h at pH 7.4 
[27] 
 
2-fluoroadenine arabinoside 
5′-triphosphate 
13-33 - 58-373 - - 12-72 h [28] 
Hydroxyapatite Ibuprofen 16.9-49.1 - 
20 in 
diameter; 
100 in 
length 
- - 
0-100 min in simulated body 
fluid 
[29] 
Iron 
Doxorubicin 33 88.4 
209.6-
601.8 
0.281-
0.411 
- 
>15 h at pH 4.8, 6.5, and 
7.4 
[30] 
10-Hydroxycamptothecin 9.8-11.8 49-59 100-300 - - 
0-5 h in phosphate buffered 
saline (PBS) at 37°C 
(hollow); >50 h in PBS at 
45°C (solid) 
[31] 
Paclitaxel 35 - 140-233 - 48 h - [32] 
Magnesium 
silicate 
Doxorubicin 68.1 - 400 - - 
7.5-10 h in PBS at pH 
5; >25 h at pH 7.4 
[33] 
MOF 
Azidothymidine 
triphosphate; 
Benzophenone 3; 
Benzophenone 4; Busulfan; 
Caffeine; Cidofovir; 
Doxorubicin; Ibuprofen; 
Urea 
Up to 69.2 Up to 85.5 50-350 - - 
Azidothymidine triphosphate 
and cidofovir 0-1 d; 
Doxorubicin 1-1.5 d, in 
simulated physiological 
conditions 
[11b] 
Caffeine 42-43 - 141-240 <0.2 
24 h in water 
and RPMI 
medium 
0-2.5 h in PBS; >25h in 
water and RPMI medium 
[11c] 
Cyclooxygenase-2 14.5-16.7 - 
15 in 
diameter; 
75 in 
length 
- 11 d 2-3 d in saline [34] 
Doxorubicin 17.2 - 
125.1-
138.8 
- - 
10-12.5 d at pH 5; 22.5 d at 
pH 7.4 
[35] 
Doxorubicin 65.5 95 100 - - 
5-10 h at pH 5; >60 h at pH 
7.4 
[36] 
5-Fluorouracil 33.3 - - - - 1-1.5 d in PBS [37] 
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Ibuprofen 15.9 - 200-800 - 1 month 4 h in PBS [38] 
siRNAs 12.3 81.6 128 0.116 - 
>9 h in water; 4.5-6 h in 
PBS 
[39] 
Polypeptide Doxorubicin 21.7-26.1 52.2-97.3 140 - - 
5-10 h at pH 5.5; >60 h at 
pH 6.8 and 7.4 
[40] 
Protein Doxorubicin 13.4 - 25.9-32.7 - - - [41] 
Silica 
Camptothecin; Curcumin; 
Doxorubicin; Paclitaxel; 
Tamoxifen 
Camptothecin 3.8-
51.9; Curcumin 
3.8-51.9; 
Doxorubicin 5.7-
51.5; Paclitaxel 
5.7-51.9; 
Tamoxifen 5.7-51.0 
Camptothecin 4-
52; Curcumin 4-
52; Doxorubicin 6-
51; Paclitaxel 6-
52; Tamoxifen 6-
51 
130-190 - - 
Camptothecin>24h; 
Curcumin>24h; Doxorubicin 
14-15h; Paclitaxel>24h; 
Tamoxifen 22-23h, in PBS 
[42] 
Carvedilol 32 94.95 500 - - 
>3 h at pH 1.2; t1/2 
concentration max = 4.226-
4.928 h in rats 
[43] 
Doxorubicin 4.1-38.5 77-82 200 - - 
50 h in simulated body fluid 
(pH 5.0); >150 h in 
simulated body fluid (pH 
7.4) 
[44] 
Doxorubicin 12.3 88.2 241.5 0.16 - 
5-10 h at pH 5 with 10 mM 
glutathione; >24 h at pH 7.4 
[45] 
Doxorubicin 20 100 - - - - [46] 
Doxorubicin 55 98 45-450 - - - [47] 
Doxorubicin; Gemcitabine 
Doxorubicin 32; 
Gemcitabine 40, 
- 200-400 - 2-3 weeks 
Doxorubicin>200 min; 
Gemcitabine 50-150 min, at 
pH 5 
[48] 
Ribonuclease A 19.98-42.62 - 200-500 0.10 
>48 h in 10 
µM 
glutathione 
0-5 h in 10 mM glutathione; 
40-50 h in 1 mM 
glutathione; >48 h in 10 µM 
glutathione 
[49] 
Telmisartan 
HPLC 48.5-61.2; 
TGA 48.9-59.7 
- 20-150 - - 
0-240 min in enzyme-free 
simulated intestinal fluid (pH 
6.8) 
[50] 
Co-
loading 
Drug-drug 
conjugate 
Chlorambucil; Irinotecan Near 100 - 75.7-95.8 0.15-0.217 21 d 
>50 h at pH 5.0 and 7.4; t1/2 
concentration max = 2-4 h 
in rats 
[51] 
Doxorubicin Near 100 - 89 - - >24 h [52] 
Drug-drug 
interaction 
Chlorine e6; Doxorubicin 100 
Chlorine e6 95; 
Doxorubicin 99 
70 - - 
Chlorine e6 0-5 h at pH 5.0 
and 7.4; Doxorubicin 5-10 h 
at pH 5.0, 0-5 h at pH 7.4 
[53] 
Drug-polymer 
conjugate 
Cabazitaxel 29.5 - 56.9-60.5 
0.008-
0.061 
6 months 48-72 h in mouse plasma [54] 
Camptothecin; Doxorubicin 
Camptothecin 40-
58; Doxorubicin 
18.5 
85 100-200 - - 
Camptothecin 0-10 h (pH 
7.4 with 30 U 
esterase), >100 h (pH 3.5, 
pH 5.0, pH 7.4); Doxorubicin 
[55] 
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0-4 h in PBS (pH 7.4 with 30 
U esterase); 4-8 h in PBS 
(pH 7.4) 
7-Ethyl-10-hydroxy-
camptothecin 
36 70 28.74 - 35 h 
>40 h in PBS (pH 7.4 with 0 
or 5 U esterase); 20-25 h in 
PBS (pH 7.4 with 10 U 
esterase) 
[56] 
Drug-
silsesquioxane 
conjugate 
Cisplatin 35-47 - 62.3-105.2 0.07-0.25 - - [57] 
MOF 
Caffeine 28.1 - 200-300 - 8 d >25 d in water [58] 
Nicotinic acid 75 - - - - 0-1 h in PBS [59] 
Polymer 
Camptothecin; Paclitaxel Paclitaxel 20 99 122 - - - [60] 
Ciprofloxacin 80 80 200-400  1 month 0-1h in PBS [61] 
Curcumin 49.5 99 70 - >1 year - [62] 
λ-Cyhalothrin 49.7 99 
124.1-
220.9 
0.10-0.17 14 d - [63] 
Paclitaxel 8.67-28.32 85-95 98-110 0.10-0.15 - 0-48 h at pH 7.4 [64] 
Protein Paclitaxel 27.2 95.3 217 0.034 - 48-60 h in PBS [65] 
Solid lipid Methotrexate 69-79.1 - 88.4-161 0.04-0.20 - 2-23 h in PBS [66] 
Pre-
loading 
Polymer 
Amphotericin B; 
Bulleyaconitine A; 
Curcumin; Docetaxel; 
Ibuprofen; Ketamine; 
Paclitaxel; Scutellarin 
38-58.5 >75 40-175 <0.2 
>15 months 
of lyophilized 
powder 
50-100 h in PBS containing 
0.5% w/v Tween 80 
[14] 
Camptothecin 29-52 >99 165-181 - - 
24-36 h with thiol trigger in 
PBS; >48 h without thiol 
trigger in PBS 
[67] 
Curcumin 78.5 95.8 83.2 0.81 - 100-125 h [68] 
Ketamine 39.1-41.8 64.2-71.8 98.8-107.4 0.18 
>7 d at room 
temperature 
6-14 d in PBS; t1/2 
concentration max = 79.7-
103.1 h in mice 
[69] 
Lopinavir; ritonavir 
Lopinavir 70; 
Ritonavir 14 
- 256-984 0.24-0.47 
14 months 
under 
ambient 
conditions 
t1/2 concentration max = 2-8 
h in rats 
[70] 
Paclitaxel; Sorafenib 
Paclitaxel 42.6; 
Sorafenib 45.2 
- 
Paclitaxel 
60-450; 
Sorafenib 
70-550 
<0.2 - 
>6 h at pH 1.2 and 5.0; 0-
0.5 h at pH 7.4 
[71] 
Silica Curcumin; Paclitaxel 
Curcumin 64.9; 
Paclitaxel 59.2 
Curcumin 99.9; 
Paclitaxel 99.3 
Curcumin 
60.3; 
Paclitaxel 
58.6 
Curcumin 
0.10; 
Paclitaxel 
0.17 
30 d 
40-50 h at pH 4.5; >50 h at 
pH 7.4 and in DMEM cell 
culture medium containing 
10% FBS 
[15] 
Solid lipid Ketoprofen 10.70-12.03 96.4-96.9 75-93 0.18-0.26 45 d 0-8 h in PBS [72] 
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2.1. Post-loading 
“Post-loading” is the strategy to fabricate nanocarriers first followed by drug loading to achieve 
high drug-loading nanoparticles (Figure 1a). The nanocarriers for post-loading strategy usually 
have porous structures, such as silica nanoparticles,[42-44, 46-50] carbon nanoparticles,[24-26] MOF 
nanoparticles,32,33,[34-39] iron nanoparticles,[30-32] hydrogel nanoparticles,[27] and some other 
nanoparticles (calcium silicate hydrate,[23] magnesium silicate,[33] and hydroxyapatite[29]). Due 
to their intrinsic properties, these porous materials provide high surface area, tunable pore size 
and volume, and easy chemistry for functionalization.[73] Other non-porous materials have also 
been explored for post-loading strategy, including polypeptide and protein.[40-41] Guest 
molecules can be post-loaded into these non-porous carriers through noncovalent hydrophobic 
interaction, electrostatic attraction, hydrogen bond, and π–π stacking.[74] Nanoparticles 
fabricated using this strategy can achieve 11.8-68.1% drug loading (Table 1). 
 
2.1.1. Silica nanoparticles 
Silica is one of the most widely used material for fabricating high drug-loading nanoparticles 
via post-loading strategy. Since mesoporous silica nanoparticle (MSN) was first explored for 
drug delivery in 2001,[75] MSN has been loaded with various drugs for potential applications 
in cancer therapy, bone/tendon tissue engineering, diabetes, and anti-inflammation.[76] MSNs 
have many favorable characteristics including high surface area (>1,000 m2/g), high porosity, 
tunable pore sizes, and tailorable porous structure. These properties make them promising 
candidates for high drug loading.  
Numerous drugs have been successfully encapsulated in silica nanoparticles with high loadings 
(20.0-61.2%, Table 1), such as camptothecin, carvedilol, curcumin, doxorubicin (DOX), 
gemcitabine, paclitaxel (PTX), tamoxifen, and telmisartan.[42-44, 46-50] Successful drug loading 
have been achieved based on various mechanisms including hydrophobic interaction, 
electrostatic interaction, hydrogen bonding, and van der Waals interactions. When using MSNs 
as drug carriers, a weakly acidic condition is important for improving their drug loading. For 
example, the drug loading of DOX-loaded MSN was 13.1% higher at pH 6.0 than 7.4.[77] The 
MSNs coated by polydopamine could also improve their drug loading significantly.[78] Zhang 
et al. synthesized mesoporous MSNs with different pore sizes (3.6, 7.8 and 12.9 nm in 
diameter).[50] A hydrophobic drug telmisartan was post-loaded in the MSN through weak 
hydrogen bond between the carboxyl group of the drug and silanol group of the MSN. Its 
release rate positively correlated with the pore size, the larger the pore size the quicker the drug 
release. However, all three MSNs had a t1/2 release of less than 15 min because of the open 
pore structure and weak interactions between the drug and the nanocarrier. To better control 
the drug release, they modified the MSN surface with amine groups to enhance its alkalinity 
thus strengthening the interaction between the acidic drug molecules and the nanocarrier. The 
t1/2 release time of amine-functionalized MSNs were significantly increased to ~120 min. 
 
In addition to chemical functionalization, designing covering materials such as polymers, 
proteins or nanoparticles as gatekeepers can also prolong the release profile. Furthermore, 
gatekeepers can be engineered to offer different trigger-release functions. Croissant et al. 
developed a smart dual-drug loaded MSN with gold clusters as the gatekeeper enabling 
triggered release. The negatively charged gold nanoclusters (AuNC) were synthesized using 
bovine serum albumin (BSA) proteins, and DOX was loaded BSA-gold clusters based on their 
electrostatic and hydrophobic interactions. GEM was trapped in the pores of the amine-
functionalized positively charged MSNs. High drug loadings of 32% (DOX) and 40% 
10.1002/cplu.202000496
Ac
ce
pt
ed
 M
an
us
cr
ip
t
ChemPlusChem
This article is protected by copyright. All rights reserved.
9 
 
(gemcitabine, GEM) were achieved.[48] The negatively charged gatekeeper was able to 
electrostatically bind to the MSN and effectively block the pores at physiological pH, but in 
acidic environments such as lysosome, the AuNC gatekeeper became protonated and reversed 
its charge from -30 to 4 mV. As a result, the electrostatic repulsion detached the gatekeeper 
from the MSN, leading to a rapid drug release. In addition to pH triggered release, many 
different gatekeepers have been developed for various triggered release such as light, redox, 
temperature, etc.[74b] Gong et al. designed a redox-responsive MSN nanocarrier using thiol-
modified PEG (PEG-SH) as a gatekeeper. Triggered drug release can be achieved using 
reduction agents such as glutathione (GSH). 
 
Depending on the pore size of MSNs, various drugs can be loaded. Normally, small pores are 
loaded with small drug molecules, whereas bigger pores can be loaded with therapeutic 
macromolecules such as proteins, DNAs.[76, 79] The pore size not only determines the size of 
cargos, but also allows different biological responses. Yang et al. developed a structure-
dependent and GSH-responsive biodegradable MSN for the delivery of ribonuclease A (Figure 
2).[49] MSNs were synthesized with larger pores of 4.6 and 14 nm using a di-sulfide bond 
containing silica precursor bis(triethoxysilylpropyl)tetrasulfide and a normal silica precursor 
1,2-bis(triethoxysilyl)ethane, respectively. The small-pore MSN (S-MSN) exhibited similar 
degradation and release rates in cancer cells and normal cells, while the large-pore MSN (L-
MSN) demonstrated faster release rates in cancer cells but slower rates in normal cells, 
suggesting its potential in targeted drug release.  
 
 
Figure 2. Pore size dependent degradability of nanoparticles in normal and cancer cells. (A) 
The disulfide bond is broken by GSH due to reduction. (B) Schematic illustration of (I) the 
composition of L-MSN, (II) S-MSN, (III) L-MSN, (IV) normal cells, (V) S-MSN, and (VI) L-
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MSN degradation in normal cells, (VII) cancer cells, (VIII) S-MSN, and (IX) L-MSN 
degradation in cancer cells. Reproduced from Ref. [49] with permission. Copyright 2016 
American Chemical Society. 
2.1.2. Carbon nanoparticles 
In contrast to MSNs, mesoporous carbon nanoparticles (MCNs) can be engineered to have even 
higher surface areas (as high as 2,000 m2/g).[80] In addition, some studies suggested that MCNs 
are more biocompatible than MSNs.[24] However, unlike MSN, MCN is inherently hydrophobic, 
which is advantageous for loading hydrophobic drugs due to strong π-π stacking and/or 
hydrophobic interactions between drugs and the carbonaceous framework, but challenging for 
administration. Therefore, it is critical to make MCNs hydrophilic. Various methods have been 
developed for MCN surface modification including introducing hydrophilic functional groups 
such as carboxyl, hydroxyl, and sulfonic groups, and hydrophilic polymers such as PEG and 
hyaluronic acid.[24-26] Zhou et al. used a template free method to synthesize DOX loaded MCN 
using phenol, formaldehyde, and Pluronic F127 as carbon sources.[81] To improve the 
hydrophilicity of the MCN, hyaluronic acid was covalently conjugated on the MCN. However, 
the drug loading was only 4.1% due to its relatively low specific surface area (~500 m2/g). A 
template-based carbonization can significantly enhance the surface area thus improving drug-
loading capacity. Li et al. used MSN as a core template, followed by carbonization from oxalic 
acid to synthesize a silica-carbon core-shell nanoparticle.[25] Subsequent silica removal by 
hydrofluoric acid created cavity cores resulting in a much higher surface area of 1400 m2/g. 
The resultant MCN was then covalently conjugated with a hydrophilic polymer poly(acrylic 
acid) via a linker to enhance the water dispersity and sustained release. This hydrophilic MCN 
achieved a maximum 51.9% high drug loading of DOX. 
 
2.1.3. MOF nanoparticles 
MOF is a big family of porous nanomaterials, and has gained wide research interest for making 
high drug-loading nanoparticles. Various transition metal ions and multidentate organic ligands 
functioning as building blocks can self-assemble into MOF nanoparticles under mild 
conditions. Due to the inherent high porosity of MOFs, their specific surface area can reach as 
high as 10,450 m2/g.[82] As the pores in MOFs are usually less than 2 nm,[83] the pores inside 
MOF nanoparticles are suitable for post-adsorption of small therapeutic molecules instead of 
macromolecules such as protein. On the other hand, the metal ions on the surface of MOF 
nanoparticles can bind biomolecules such as protein and DNA via coordination bonds. Many 
drugs have been incorporated in MOF structures through post-loading strategy including 
azidothymidine triphosphate, busulfan, caffeine, cidofovir, cyclooxygenase-2, DOX, 5-
fluorouracil, ibuprofen, and siRNAs.[11b, 11c, 34-39] 12.3-65.5% drug loadings have been achieved 
(Table 1). 
 
Drug loading in MOF nanoparticles is dependent on their pore volumes, size ratio of drugs to 
MOF pores, as well as the strength of interactions between drugs and MOFs such as 
hydrophobic interaction, π–π stacking, and coordinate bonds. So when designing drug loaded 
MOF nanoparticles, the sizes of drugs and cages/tunnels of MOFs should be carefully 
considered. For example, drug molecules should be small enough to access the cage/tunnel, 
and wasted space should be minimized by matching the size of drugs and MOF cages. 
Horcajada et al. developed a platform technology to synthesize various MOF nanoparticles 
(MIL-53, MIL-88A, MIL-88Bt, MIL-89, MIL-100 and MIL-101_NH2; MIL, Materials of 
Institut Lavoisier) from iron(III) and several organic linkers.[11b] These MOF nanoparticles 
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were able to load various cargoes including azidothymidine triphosphate, benzophenone 3, 
benzophenone 4, busulfan, caffeine, cidofovir, DOX, ibuprofen, and urea with up to 69.2% 
drug loading. Moreover, the iron in these MOF particles makes them suitable for magnetic 
resonance imaging thus opening opportunities for theranostic applications.  
Apart from loading single drug, dual drugs can also be incorporated in MOF nanoparticles. He 
et al. developed nanoscale MOFs for the co-delivery of cisplatin (Cis) and small interfering 
ribonucleic acids (siRNAs) to drug-resistant ovarian cancer cells.[39] These MOFs with 
hexagonal-plate morphologies were loaded with a cisplatin prodrug by adsorption to the pores, 
while the siRNA was coordinated to metal sites on the MOF surfaces with 12.3% cisplatin drug 
loading and 81.6% siRNA encapsulation efficiency.  
 
2.1.4. Iron nanoparticles 
Iron-based magnetic nanoparticles have the characteristics of porous materials aforementioned 
such as large pores and high surface area which are beneficial for high drug loading, and they 
also provide site-specific passive targeting capabilities under magnetic fields due to the strong 
magnetization. Moreover, iron-based nanoparticles have great potentials in magnetic resonance 
imaging and pH-responsive drug release, making them ideal candidates for theranostic 
applications. Also, iron oxide nanoparticles has been approved for clinical applications. They 
have been used for loading various drugs such as DOX, 10-hydroxycamptothecin, and PTX 
with high loadings through hydrophobic interactions and π–π stacking.[30-32] Their maximum 
loadings ranged from 11.8-35.0% (Table 1). Luo et al. fabricated mesoporous magnetic 
colloidal nanocrystal clusters (MCNCs) stabilized by poly(γ-glutamic acid) (PGA) as 
hydrophobic drug delivery vehicles and achieved 35% drug loading of the anticancer drug PTX 
because of their high porous structure.[32] Wu et al. developed DOX-loaded Prussian blue-based 
nanocages and achieved 33% drug loading and 88.4% encapsulation efficiency.[30] The 
nanocages could be triggered to release DOX by both acidic environment and near infra-red 
(NIR) laser irradiation. Moreover, Prussian blue, as an NIR-driven photothermal conversion 
agent in combination with DOX made this nanocage dual-mode photo- and chemo- therapeutic 
nanomedicine.  
 
2.1.5. Nanogels 
Nanogels are hydrogel nanoparticles that combine the properties of both hydrogels and 
nanomaterials. They have high water content, tunable physical and chemical properties, good 
mechanical properties, and biocompatibility. The loading mechanism is normally electrostatic 
interaction between the drug and the gel polymer. Vinogradov et al. developed an anticancer 
drug 2-fluoroadenine arabinoside 5′-triphosphate-loaded nanogel using a modified 
emulsification-solvent evaporation method and achieved 33% drug loading.[28] The nanogel 
contained cationic polymer poly(ethylenimine) which attracted the anionic drug by 
electrostatic interaction. The nanogel was enveloped by PEG facilitating sustained release and 
providing protection of the encapsulated drug against enzymatic degradation. In contrast, Pan 
et al. synthesized nanogel using an anionic polymer poly(methacrylic acid) (PMAA) to load 
cationic drug DOX via electrostatic interaction.[27] They achieved a drug loading of 42.3% with 
an encapsulation efficiency of 95.7%. Furthermore, the nanogel was redox/pH dual stimuli-
responsive due to di-sulfide bond in the polymer (Figure 3). 
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Figure 3. PMAA nanogels for redox stimuli-responsive drug release. Reproduced from Ref. [27] 
with permission. Copyright 2012 Elsevier Ltd. 
 
2.1.6. Other nanoparticles 
In addition to those nanoparticle described above, protein-based nanocarriers are another 
important type of nanomaterials for drug delivery. They offer several advantages, e.g., 
excellent biocompatibility, biodegradability, tuable structure, and diverse functions. Drugs can 
be incorporated into protein nanoparticles via either covalent or non-covalent interactions. 
Albumin is a natural protein carrier for various hydrophobic molecules via reversible non-
covalent interactions. Also albumin can bind to the extracellular matrix glycoprotein SPARC 
which is related to poor prognosis in many cancers, this interaction promotes the accumulation 
of albumin in the tumor.[84] As one of the most successful stories in cancer nanomedicine, 
Abraxane®, an albumin–bound PTX nanoparticle formulation has been approved by the US 
FDA for the treatment of metastatic breast cancer with a drug loading of around 10%.[85] Other 
drugs have also been investigated for making albumin-drug nanomedicines. For example, Yang 
et al. used bovine serum albumin nanoparticles to entrap 10-hydroxycamptothecin but with a 
low drug loading of 2.2% due to inadequate attachment sites.[86] Re-engineering protein 
sequence to incorporate more hydrophobic amino acids for more binding sites is a feasible 
approach to increase drug loading. Ren et al. attempted to load anti-tumor drug DOX into the 
hollow cavity of an engineered protein nanoparticle.[41] Several variants of the E2 subunit of 
pyruvate dehydrogenase were designed via structural modeling and protein engineering. A 
maximum drug loading of 13.4% was achieved with up to 390 DOX molecules loaded in one 
nanoparticle. Recently, two-dimensional black phosphorus nanomaterials are developed as a 
delivery platform,[87] which can be used for high loading of theranostic agents[88] as well as a 
co‐delivery system for gene/chemo/photothermal therapy.[89] Additionally, numerous other 
materials such as calcium silicate hydrate,[23] hydroxyapatite,[29] magnesium silicate,[33] and 
polypeptide[40] have also been developed using similar post-loading strategies to produce high 
drug-loading nanoparticles with drug loadings from 26.1-69.6% (Table 1). 
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2.2. Co-loading 
“Co-loading” herein is to describe a strategy that a drug is loaded or encapsulated during the 
formation of nanoparticles (Figure 1b). Various systems have been developed including pure 
drugs,[51, 53] drug-polymer conjugate,[54-56] drug-silsesquioxane conjugate,[57] MOF with drug 
incorporated,[58-59] solid-lipids,[66] proteins,[65] and polymers[60-64]. Covalent binding plays an 
important role for those conjugated systems, while hydrophobic, electrostatic, and π-π 
interactions are important for polymers, proteins, etc. By using co-loading strategy, 18.5 to 
100.0% drug loadings have been achieved, with nanoparticle sizes ranging from 29 to 400 nm 
(Table 1). 
 
2.2.1. Drug-polymer conjugates 
Drug-polymer conjugates often take advantage of the intrinsic properties of hydrophobic drugs 
and hydrophilic polymers to facilitate the self-assembly of amphiphilic drug-polymer 
molecules. Several drugs including camptothecin, DOX, and 7-ethyl-10-hydroxy-
camptothecin have been explored to form such drug-polymer conjugates (Table 1).[54-56] Zhang 
et al. produced nanoparticles with 36% drug loading using drug-polymer conjugate through 
self-assembly.[56] The amphiphilic drug-polymer conjugate was synthesized by a very low 
molecular weight oligo (ethylene glycol) (OEG) chain as the hydrophilic part and a 
hydrophobic chemotherapeutic agent SN38 (7-ethyl-10-hydroxy-camptothecin) via ester bond.  
Bteich et al. synthesized carboxymethyl cellulose-based nanoparticles with a drug loading of 
29.5% using flash nanoprecipitation.[54] A hydrophobic anticancer drug cabazitaxel was 
conjugated to the PEGylated carboxymethyl cellulose to form the amphiphilic drug-polymer 
conjugates for self-assembly. Similarly, drug-silsesquioxane conjugate has also been 
developed for making cisplatin-loaded silica nanoparticles with drug loading of 35-47%.[57]  
 
2.2.2. Drug-drug systems 
Drugs can be self-delivered by using drug-drug conjugates to achieve ~100% of drug loading. 
An amphiphilic drug-drug conjugate was synthesized using a hydrophilic anticancer drug 
irinotecan (Ir) and a hydrophobic anticancer drug chlorambucil (Cb) through a hydrolyzable 
ester linkage (~100% drug loading).[51] The Ir-Cb conjugate self-assembled to nanoparticles by 
nanoprecipitation. They exhibited relatively slow release in PBS (pH 7.4) and PBS containing 
10% fetal bovine serum, but a faster release in a weakly acidic environment (pH 5.0) due to 
the hydrolysis of the ester bond between two drugs. Similarly, Song et al. synthesized a drug-
drug conjugate using a disulfide bond to link two DOX molecules (DOX-SS-DOX).[52] The 
DOX-SS-DOX conjugates self-assembled into nanoparticles via nanoprecipitation with a drug 
loading of near 100%. The DOX-SS-DOX nanoparticles demonstrated a reduction-responsive 
release due to the presence of disulfide bonds. 
 
Drug-drug interaction is another similar strategy to achieve 100% drug loading. Instead of 
covalent conjugation of one hydrophobic drug to one hydrophilic drug, some drugs can self-
assemble into amphiphilic nanoparticles via non-covalent interactions. Zhang et al. designed a 
pure drug nanoparticle by the self-assembly of a photosensitizer (chlorine e6, Ce6) and DOX 
through electrostatic, π−π stacking and hydrophobic interactions with 100% drug loading as 
well as high encapsulation efficiency of more than 95% for Ce6 and 99% for DOX (Figure 
4).[53] The drug-drug nanoparticle showed significantly slower release in PBS (pH 7.4), but 
slightly faster DOX release under a weakly acidic environment (pH 5.0) due to the protonation 
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of the amino group of DOX. These drug-drug nanoparticles illustrated a good cellular uptake 
in vitro as well as a good synergistic antitumor effect in vivo. 
 
 
Figure 4. Carrier-free nanoparticles via co-assembly of DOX and Ce6. Reproduced from Ref. 
[53] with permission. Copyright 2016 American Chemical Society. 
 
2.2.3. MOF nanoparticles 
Unlike the post-loading of drugs in MOF particles aforementioned, drugs can also be loaded in 
MOF during its formation. In some cases, drug molecules themselves can act as the building 
blocks, together with the metal ions to form MOF structure. Such MOFs are also called 
MBioFs. The co-loading strategy has been used to load drugs including caffeine and nicotinic 
acid with high drug loadings of 28.1-75% (Table 1).[58-59] Caffeine was loaded to zeolitic 
imidazolate frameworks (ZIF-8) using a simple one-step mixing method.[58] The MOF particles 
showed a sustained caffeine release for 27 days. Similarly, Huxford et al. used metal ions and 
an anti-cancer drug methotrexate to form MBioF particles via coordinate interactions between 
drug molecules and metal ions, followed by coating a double-layer lipid. Such solid-lipid 
MBioF nanoparticles had very high drug loadings of 69-79.1%.[66] 
 
2.2.4. Polymer nanoparticles 
Different from the above co-loading methods that often employ covalent bindings, polymers 
can encapsulate drugs through non-covalent hydrophobic interactions using nanoprecipitation. 
However, most of these systems have low drug loadings usually below 10%. Controlling the 
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mixing time during nanoprecipitation is a critical factor to improve drug loading. D-α-
Tocopheryl polyethylene glycol 1000 succinate (TPGS or Vitamin E TPGS) is a commonly 
used nonionic surfactant and can be used to improve the drug loading of polymer 
nanoparticles.[90] Various drugs (camptothecin, ciprofloxacin, curcumin, λ-cyhalothrin, and 
PTX) and polymers (pluronic F-127, dextran sulfate, poly(lactide)-poly(ethylene glycol) 
(PLA-PEG), and poly(N-vinylpyrrolidone)-b-poly(ε-caprolactone)) have been used to form 
nanoparticles with drug loadings ranging from 20 to 80% (Table 1).[60-64] Flash 
nanoprecipitation, first introduced in 2003,[91] was designed to achieve a mixing time less than 
the nucleation and growth time of a nanoparticle, and it is a rapid, scalable, and continuous 
bottom-up approach to produce monodispersed nanoparticles with tunable particle sizes and 
high drug loading.[54, 62] Two mixing devices, confined impinging jets mixer and multi-inlet 
vortex mixer, have been extensively used for flash nanoprecipitation.39 λ-cyhalothrin loaded 
poly(ethylene glycol)-poly(d,l-lactide) (PEG-PDLLA) nanoparticles were produced by flash 
nanoprecipitation using a multi-inlet vortex mixer, which achieved 49.7% drug loading and 
99% encapsulation efficiency (Figure 5).[63] They were able to remain stable for up to half of a 
month during storage at both 0 and 25 °C.  
 
 
Figure 5. Multi-inlet vortex mixer for preparing λ-cyhalothrin-loaded PEG-PDLLA 
nanoparticles. Reproduced from Ref. [63] with permission. Copyright 2018 American Chemical 
Society. 
 
2.2.5. Protein nanoparticles 
Similar to MBioFs, drugs can also be incorporated in protein nanoparticles during self-
assembly. A PTX-loaded BSA nanoparticle was produced with drug loading of 27.2% and 
encapsulation efficiency of 95.3% by a desolvation method. [65] BSA in water was mixed with 
the PTX in ethanol using a peristaltic pump followed by the addition of glutaraldehyde solution 
to crosslink the amino groups in the nanoparticles. The obtained nanoparticles showed an initial 
burst release in the first 12 hours followed by a sustained release. 
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2.3. Pre-loading 
Pre-loading is a strategy that produces drug nanoparticles first, followed by the formation of a 
shell stabilizing and protecting the drug core (Figure 1c). By tuning the shell thickness, 
nanoparticles with high drug loading can be made.[92] Also, the core-shell structure provides 
several appealing advantages. Firstly, the shell provides a diffusion barrier for controlling the 
drug release, and it also protects the drug core from external degradative environment. 
Moreover, the shell can be engineered to offer tunable release (e.g., sustained[93] or stimuli-
responsive release[94]),[95] and it can also be modified for various biological applications by 
conjugating targeting moieties, linkers spacers, or other functional moieties such as drug 
delivery, biosensing, imaging, diagnostics.[92c, 96] Notably, most of the nanoparticle systems 
using this strategy adopt polymers as their shell material,[14, 67-71, 97] because of their excellent 
biocompatibility, biodegradability, and simple fabrication methods.[3b] Some other materials 
silica[15] and lipids[72] have also been attempted. Drug loadings for nanoparticles fabricated 
using this strategy range from 12.0 to 78.5% with sizes from 40 to 984 nm (Table 1). 
 
Some hydrophobic drugs (e.g. curcumin) are able to form drug nanoparticles themselves and 
remain stable from minutes to hours without any stabilizers or surfactants. So the pre-loading 
strategy can be adopted to produce drug nanoparticle first followed by covering them using 
different polymer materials to improve their long-term stability.[21]  Zhang et al. developed a 
method to cover curcumin drug nanoparticles using a polymer, and achieved 78.5% drug 
loading.[67] Curcumin dissolved in tetrahydrofuran was quickly injected into water under 
stirring to produce curcumin nanoparticles by nanoprecipitation. Then, poly(maleic anhydride-
alt-1-octadecene)-poly(ethylene glycol) was used to cover the surface of the curcumin 
nanoparticles by ultrasonication through hydrophobic interactions. Due to the protection from 
the outer PEG layer, curcumin nanoparticles covered with the polymer showed a slower release 
compared to the plain curcumin nanoparticles. In vitro and in vivo experiments illustrated better 
therapeutic efficacy of the curcumin-polymer nanoparticles compared to free curcumin.  
 
For those drugs unable to form stable nanoparticles due to the strong π-π interaction between 
drug molecules, conjugation of two drug molecules to form freely rotated drug dimers could 
be an alternative strategy to obtain stable drug nanoparticles. Cai et al. fabricated camptothecin 
(CPT) loaded PLA-PEG nanoparticles with a dimeric drug core and a polymer shell structure 
with over 50% drug loading and close to 100% encapsulation efficiency.[67] They designed and 
synthesized a dimeric CPT derivative, CPT-SS-CPT by the conjugation of two CPT molecules 
via carbonate linkages which can be cleaved by a reducing reagent. Unlike single CPT 
molecules with strong π-π stacking tendency, which could result in large aggregates after 
nanoprecipitation, the dimeric CPT-SS-CPT had increased intermolecular hydrophobic 
interactions but less π-π stacking. Therefore, the CPT-SS-CPT can be dissolved in DMF and 
precipitated using water to form drug nanoparticles. The nanoparticles with drug-core and 
polymer-shell were produced by nanoprecipitation with a mixture of CPT-SS-CPT and PLA-
PEG as a solvent precursor and water as an anti-solvent. The resulting nanoparticles showed 
good stability under physiological conditions as well as a controlled release without any burst 
release. 
 
Also, other methods such as emulsion templated freeze-drying can be used to produce drug 
nanoparticles.[97] Ritonavir (RTV)-boosted lopinavir (LPV) oral liquid formulation is a 4:1 
LPV: RTV combination for the treatment of the pediatric HIV infection as recommended by 
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the World Health Organization. High drug-loading (~70%) formulations of LPV and 
LPV/RTV drug nanoparticles were fabricated using an emulsion templated freeze-drying 
method.[70] Briefly, the drugs in chloroform were mixed with an aqueous solution containing a 
polymer and surfactant, and the mixture was emulsified using ultrasonication. Then, the 
resulting solution was cryogenically frozen immediately and lyophilized to obtain a dry powder 
of drug-loaded nanoparticles. After screening a 160-component library, two optimal 
formulations were developed showing high drug loading, good reproducibility and low 
surfactant content (70% LPV and 56/14% LPV/RTV, both with 20% polyvinyl alcohol and 
10% α -tocopherol polyethylene glycol succinate). 
 
Solid lipid nanoparticles have also been synthesized to encapsulate poorly soluble drugs with 
high drug loading. A Ketoprofen loaded solid lipid nanoparticle was prepared from a mixture 
of beeswax and carnauba wax using Tween 80 and egg lecithin as emulsifiers with 12.03% of 
drug loading and 97% of encapsulation efficiency.[72] Nanoemulsions were formed using a 
mixture of beeswax, carnauba wax, lecithin, and ketoprofen at 90°C in the presence of Tween 
80. Then following their dispersion in cold water under stirring, the outer wax layer of the 
nanoemulsion droplets was solidified resulting in the formation of solid lipid particles. These 
lipid nanoparticles remained stable for 45 days without any drug leakage, but showed a burst 
release within the first hour then a sustained release. The nanoparticles with more beeswax 
demonstrated faster drug release compared to those having more carnauba wax. 
 
Drug-core silica-shell nanoparticles with high drug loading (65%) and high encapsulation 
efficiency (99%) have also been developed using a modular biomolecule templating method 
(Figure 6).[15] Bifunctional amphiphilic peptides were designed to not only stabilize 
hydrophobic drug nanoparticles but also induce biosilicification at the surface of drug 
nanoparticles thus making silica shell. Typically, a solvent solution containing a drug was 
mixed with a peptide solution. Upon mixing drug nanoparticles were formed via 
nanoprecipitation and stabilized by the peptides. A subsequent addition of a silica precursor 
induced the biosilicification of a silica shell by the peptide resulting in the formation of drug-
core silica-shell nanoparticles. By tuning the silica shell thickness and the size of the drug 
nanoparticles, tunable drug-loadings can be achieved. These core-shell nanoparticles exhibited 
very slow release at pH 7.4 but an accelerated release at pH 4.5 due to the faster degradation 
of the silica shell in acidic solutions. In comparison with low drug-loading nanoparticles, the 
high drug-loading counterparts showed enhanced cancer cellular uptake, improved anti-tumor 
efficacy and reduced side effects. 
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Figure 6. Formation of drug‐core silica–shell nanocomposites using a bifunctional peptide. a, 
Illustration of the synthesis process of drug‐core silica–shell nanocomposites. Scale bar: 50 
nm. b, Representative TEM image of curcumin‐core silica–shell nanocomposites. Scale bar: 1 
μm. Reproduced from Ref. [15] with permission. Copyright 2019 Wiley‐VCH Verlag GmbH & 
Co. KGaA, Weinheim. 
 
Microfluidic methods have been widely used for making drug-loaded polymer nanoparticles 
using nanoprecipitation but normally with low drug loading (about 1% to 7%),[98] mainly due 
to the distinct precipitation time of the drug and polymer. Sequential nanoprecipitation, that is, 
drugs precipitate first to form drug nanoparticles, followed by polymer precipitation 
encapsulating the drug nanoparticles, is a new approach to improve drug loading. Liu et al. 
developed a microfluidic platform technology to achieve sequential nanoprecipitation of drugs 
and polymers.[71] Basically, a solvent phase containing a hydrophobic drug (PTX, sorafenib) 
and a pH-responsive polymer hypromellose acetate succinate was pumped into the microfluidic 
device to mix with a basic solution, so drug nanoparticles were precipitated. Then the 
introduction of an outer stream containing a third acidic solution induced the precipitation of 
polymer thus forming drug-core polymer-shell nanoparticles with 45.2% drug loading ((Figure 
7). The obtained nanoparticles showed a controlled drug release profile under different pH 
conditions owing to the pH-responsive property of the polymer. Moreover, the extremely short 
time interval between the sequential nanoprecipitation processes of the drug and polymer made 
it possible to have stable nanoparticles in the absence of any stabilizers. This microfluidic 
approach has also been successfully used for high-throughput manufacture of high drug-loaded 
polymer nanoparticles.   
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Figure 7. Superfast microfluidic sequential nanoprecipitation platform. Inner fluid 1: drug and 
polymer precursors dissolved in solvent; Inner fluid 2: basic solution as the non-solvent for 
drug; Outer fluid: Acidic solution as the non-solvent for polymer. Reproduced from Ref. [71] 
with permission. Copyright 2017 American Chemical Society. 
 
Alternatively, sequential nanoprecipitation can be achieved using nanoprecipitation in bulk 
solutions. Liu et al. developed a drug-core polymer-shell nanoparticle with high drug-loading 
of 58.5% by a bulk sequential nanoprecipitation method using various polymers (poly(lactic-
co-glycolic acid) (PLGA), PLGA-PEG, PLA-PEG and shellac) and drugs (PTX, docetaxel, 
curcumin, ketamine, ibuprofen, amphotericin B, scutellarin and bulleyaconitine A, Figure 
8).[14] Different from the microfluidic approach which controls the sequence of introducing 
non-solvents to precipitate drug and polymer sequentially, this bulk method was to control the 
precipitation time of drug and polymer by using a solvent mixture containing multiple solvents. 
So when the solvent mixture solution containing the drug and polymer was mixed with an anti-
solvent aqueous solution, drug nanoparticles precipitated firstly followed by polymer thus 
forming drug-core polymer-shell nanoparticles due to the intrinsic sequential precipitation time 
of the drug and polymer. The resultant high PTX-loaded nanoparticles demonstrated enhanced 
therapeutic effect and improved safety compared to the low PTX-loaded nanoparticles 
produced by the traditional nanoprecipitation method. Furthermore, by using different 
polymers or double polymers, these nanoparticles showed various controlled release profiles. 
For example, ketamine-loaded polymer nanoparticles (~40% drug loading) produced using this 
sequential nanoprecipitation method exhibited a nearly first-order release profile as well as an 
improved pharmacokinetic profile with a very long t1/2 (79.7-103.1 h) of max drug 
concentration.[69] Compared to the t1/2 of free ketamine (0.6 h) and other high drug-loading 
nanoparticles (2-8 h, Table 1),[43, 51, 70] these high ketamine-loading nanoparticles demonstrated 
excellent stability and sustained release. 
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Figure 8. Sequential nanoprecipitation method for the synthesis of high drug-loading 
nanoparticles. Reproduced from Ref. [14] with permission. Copyright 2020 Wiley‐VCH Verlag 
GmbH & Co. KGaA, Weinheim. 
 
3. Summary and Outlook 
Recent progress in nanotechnology has promoted the development of numerous drug-loaded 
nanoparticles. Among these nanoparticles, a vast diversity of nanoparticle systems with high 
drug loading (≥10%) has been developed using post-loading, co-loading, and pre-loading 
methods for drug delivery applications. In contrast to low drug loading (<10%) nanoparticles, 
high drug loading nanoparticles offer many advantages for drug delivery applications. 
Post-loading is easy and universal for loading various drugs, especially for those mesoporous 
materials. However, these nanoparticles face challenges including low loading efficiency and 
undesirable burst release due to the unspecific binding or adsorption of drugs on particle 
surface. Coating a thin layer of extra material as the gatekeeper represents a common and 
effective approach to mitigate the initial burst release, but it also has limitations such as extra 
steps for coating and purification which could lead to the decrease of drug loading and 
unwanted drug degradation, etc.. The co-loading method often requires the least steps for 
making high drug loading nanoparticles as drugs are loaded during the process of nanoparticle 
formation. However, drug-conjugate self-assembled nanoparticles tend to be unstable due to 
the reversible self-assembly and dis-assembly process. Also, although a maximum of 100% of 
drug loading could be obtained by using drug-drug conjugates, it is difficult to develop a 
universal strategy for all drugs. The pre-loading approach represents a new and promising 
strategy for making core-shell nanoparticles with high drug loading. This core-shell structure 
offers many advantages, such as separate engineering possibilities of the core and shell 
materials for controlled release and targeting delivery. However, this method has mainly been 
developed for loading hydrophobic drugs, especially for those drugs that are able to form stable 
drug nanoparticles.  
Despite the rapid progress of high drug-loading nanoparticles in research at laboratory scale, 
fundamental understanding of the effect of drug loading on their pharmacokinetics, 
pharmacodynamics, biodistribution and therapeutic effect is limited. Whether there exists an 
optimum drug loading which allows highest drug dose but minimum side effects remains a 
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question, more preclinical and clinical studies are critical for the development of nanomedicine 
in this field. Moreover, the biocompability, degradability and safety of carrier materials also 
play pivotal roles in their practical clinical applications. Then the large-scale production of high 
drug-loading nanomedicine represents another challenge, so the simpler the synthesis method 
the better chance in scaling up the production. Although it has been more than two decades 
since the first Doxil clinical approval in 1995, there is a still long way to go to realize the full 
potential of nanomedicines in treating various diseases, which requires significant 
multidisciplinary and collaborative efforts. 
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